Skip to main content

Postmenopausal Women

2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
EverolimusPhase 21 trial
Active Trials
NCT01231659Completed72Est. Apr 2017
Best-Link Bioscience
Best-Link BioscienceChina - Shanghai
1 program
1
BL0175Phase 11 trial
Active Trials
NCT07366632Not Yet Recruiting27Est. Dec 2026
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
EverolimusPHASE_21 trial
Active Trials
NCT06789900Active Not Recruiting136Est. Oct 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo NordiskEverolimus
SandozEverolimus
Best-Link BioscienceBL0175

Clinical Trials (3)

Total enrollment: 235 patients across 3 trials

Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women

Start: Oct 2024Est. completion: Oct 2026136 patients
Phase 2Active Not Recruiting

Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Start: Aug 2011Est. completion: Apr 201772 patients
Phase 2Completed

A Study of Single Dose of BL0175 in Postmenopausal Women

Start: Jan 2026Est. completion: Dec 202627 patients
Phase 1Not Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.